Vor Biopharma has shifted focus to immunology, raising over $500 million in 2025 to support the US approval process for telitacicept, a drug already approved in China for multiple uses. The company holds $530 million in cash, extending its financial runway to 2029, but investors should be cautious due to potential dilution from outstanding warrants and equity plans. Telitacicept must complete pivotal Phase 3 trials in the US, with data expected by 2027. Given the intense competition and lack of near-term catalysts, the analyst maintains a Hold rating on Vor Biopharma.
Law Offices of Howard G. Smith reminds investors of upcoming deadlines to file lead plaintiff motions in securities fraud class actions involving Badger Meter, PicS N.V., Verra Mobility, and Grail, Inc. The lawsuits allege these companies made mislea...
Assembli Events & Production is creating the Big Ten Conference's first fan activation at Fanatics Fest NYC, held July 16-19, 2026. This event marks the Big Ten as the first collegiate conference to join the premier sports fan festival, showcasing tr...
State Street posted strong Q2 results with earnings per share of $3.65, beating estimates and up from $2.53 last year. Quarterly revenue reached $4.05 billion, driven by a 17.2% rise in fee revenues and 18% growth in net interest income. Assets under...
U.S. farmers face high and unstable fertilizer prices due to global shipping disruptions, with nearly 70% unable to afford needed fertilizer this season. Denali Water Solutions provides a natural, low-cost fertilizer alternative made from recycled or...
Denodo Technologies released Platform 9.5, improving its AI data layer by providing trusted, governed enterprise context for AI, analytics, and data sharing. Key features include an expanded enterprise knowledge graph, metric views for consistent bus...
